Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.65 - $0.86 $65 - $86
-100 Reduced 0.56%
17,900 $13,000
Q3 2023

Nov 14, 2023

SELL
$0.65 - $1.25 $260 - $500
-400 Reduced 2.17%
18,000 $12,000
Q2 2023

Aug 14, 2023

SELL
$1.08 - $1.65 $7,992 - $12,210
-7,400 Reduced 28.68%
18,400 $22,000
Q1 2023

May 15, 2023

SELL
$0.78 - $1.42 $624 - $1,136
-800 Reduced 3.01%
25,800 $30,000
Q4 2022

Feb 14, 2023

BUY
$0.79 - $1.28 $553 - $896
700 Added 2.7%
26,600 $21,000
Q3 2022

Nov 14, 2022

BUY
$0.14 - $1.33 $84 - $798
600 Added 2.37%
25,900 $31,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $70.1M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.